These markers make otherwise difficult-to-follow cancer cells detectable during imaging. Fluorescent dyes and genetically encoded reporters provide signals that microscopy can capture, whereas bioluminescent markers support imaging of labeled cells. Selecting one of these approaches establishes the signal used to locate cells and compare their behavior across observations.
Repeated observations add a time dimension to cancer research. Rather than showing only where cells are at one moment, tracking can indicate whether they survive, move, or change as a tumor develops or treatment is administered. This temporal information helps relate cellular behavior to disease progression, treatment response, and drug resistance.
Tracking can be interpreted alongside the surrounding tissue and other cellular participants. In particular, it can help examine invasion, metastasis, and interactions between cancer cells and immune cells, while also showing changes in tumor composition. These linked observations help researchers study how local cellular behavior contributes to broader tumor progression.
Researchers first label cancer cells with fluorescent dyes, genetically encoded reporters, or bioluminescent markers. They then use microscopy or whole-body imaging to locate the labeled cells and monitor them over time. Finally, the resulting observations can be compared with tumor development, spread, cellular interactions, or treatment response.
Microscopy and whole-body imaging extend the analysis to different observational settings. Microscopy provides a route for examining labeled cells and their surrounding tissue, while whole-body imaging supports monitoring across the organism. This distinction allows researchers to connect cellular behavior with either local processes, such as invasion, or broader patterns of spread and progression.
By monitoring labeled cells during disease progression or treatment, researchers can relate survival, movement, and changes in tumor composition to treatment outcomes. This approach can reveal patterns associated with drug resistance and help evaluate how cancer cells respond to therapy. The resulting evidence supports the development of more targeted therapeutic strategies.